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Abstract
Background: Occupational therapists may have an added value in the care of patients with Parkinson’s disease
whose daily functioning is compromised, as well as for their immediate caregivers. Evidence for this added value is
inconclusive due to a lack of rigorous studies. The aim of this trial is to evaluate the (cost) effectiveness of
occupational therapy in improving daily functioning of patients with Parkinson’s disease.
Methods/Design: A multicenter, assessor-blinded, two-armed randomized controlled clinical trial will be
conducted, with evaluations at three and six months. One hundred ninety-two home-dwelling patients with
Parkinson’s disease and with an occupational therapy indication will be assigned to the experimental group or to
the control group (2:1). Patients and their caregivers in the experimental group will receive ten weeks of home-
based occupational therapy according to recent Dutch guidelines. The intervention will be delivered by
occupational therapists who have been specifically trained to treat patients according to these guidelines.
Participants in the control group will not receive occupational therapy during the study period. The primary
outcome for the patient is self-perceived daily functioning at three months, assessed with the Canadian
Occupational Performance Measure. Secondary patient-related outcomes include: objective performance of daily
activities, self-perceived satisfaction with performance in daily activities, participation, impact of fatigue, proactive
coping skills, health-related quality of life, overall quality of life, health-related costs, and effectiveness at six months.
All outcomes at the caregiver level will be secondary and will include self-perceived burden of care, objective
burden of care, proactive coping skills, overall quality of life, and care-related costs. Effectiveness will be evaluated
using a covariance analysis of the difference in outcome at three months. An economic evaluation from a societal
perspective will be conducted, as well as a process evaluation.
Discussion: This is the first large-scale trial specifically evaluating occupational therapy in Parkinson’s disease. It is
expected to generate important new information about the possible added value of occupational therapy on daily
functioning of patients with Parkinson’s disease.
Trial registration: Clinicaltrials.gov: NCT01336127.
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Background
Parkinson’s disease is the second most common neuro-
degenerative disorder. It is a complex disease affecting
both motor and non-motor systems in the brain. As a
result patients can have a wide range of deficits in per-
formance components, including mobility, balance, hand
dexterity, memory and executive functioning. As the dis-
ease progresses, effectiveness of the medication regime
often decreases, and daily functioning and social participa-
tion become increasingly compromised [1-3]. Parkinson’s
disease has a great impact on the quality of life of both
patients and their informal caregivers [4-6]. The costs of
care are high, partly due to the increasing need of support
[4]. Improvement of quality of life and reduction of
healthcare costs might be achieved by maintaining or im-
proving the patient’s skills and independence in daily
activities, and also by reducing caregivers’ burden. To ad-
dress the great variety of needs in a complex and progres-
sive disease like Parkinson’s disease, a client-centered and
multidisciplinary approach is required [7-9].
Within multidisciplinary care for Parkinson patients,
the primary role of occupational therapy (OT) is to
optimize activity performance and engagement in valued
activities and roles in the home or community context
(occupational performance). The contribution of OT in
Parkinson’s is widely recognized, but systematic reviews
reveal a lack of rigorous studies to draw conclusions
on the effectiveness of OT in Parkinson’s care [10-12].
Some studies evaluate OT as part of a multidisciplinary
intervention [13-17], but the specific contribution and
added value of OT cannot be determined from these
studies.
From 2006 to 2008 we developed guidelines for OT in
Parkinson’s disease (in Dutch), under the auspices of the
Dutch Association of Occupational Therapy with the aim
to improve uniformity and quality of OT in Parkinson’s
disease [18,19]. The guidelines cover specific methods for
occupation-based assessment of patients and their
caregivers and self-management and compensatory strat-
egies to maintain or enhance occupational performance or
occupational performance patterns in daily life.
Our hypothesis is that OT according to the Dutch
guidelines has an added value within multidisciplinary
care for patients with Parkinson’s disease and their
caregivers. We expect that addressing the complex occu-
pational performance issues from an OT perspective will
improve daily functioning, more so than if OT is not
involved. Improved daily functioning will result in
enhanced participation in daily activities among patients,
reduced caregiver burden, an improved quality of life for
both patients and caregivers, and a reduction in costs
for society. To test this hypothesis, we followed the steps
of the framework for evaluation of complex interventions
of the Medical Research Council [20,21]. Based on a phase
II exploratory trial [22] we have improved the procedures
for the currently proposed randomized controlled trial
(phase III trial). This trial, the OTiP study, evaluates the
effectiveness and cost-effectiveness of OT according to the
Dutch guidelines for OT in Parkinson’s disease.
Methods/Design
Trial design
A multicenter, assessor-blinded, two-armed randomized
controlled clinical trial will be conducted. Patients and
their caregivers will be assigned to the experimental
group or to the control group in a ratio of 2:1, respect-
ively. This way the patients have twice as much chance to
be in the intervention than in the control group. This ratio
will enhance the inclusion, whereas there will hardly be
any power loss compared to a 1:1 randomization. Ran-
domization will be based on a computerized minimization
algorithm with the following minimization factors: base-
line primary outcome measure (Canadian Occupational
Performance Measure (COPM) performance: <5; ≥5), se-
verity of disease (Hoehn and Yahr (H&Y) score: <3; ≥3),
gender and age group (<65 years; ≥65 years) of the patient,
and patient receiving physiotherapy at baseline (yes/no).
Data on observational and self-reported outcome mea-
sures will be collected at baseline, after three months
(post-intervention) and after six months (follow-up) (see
Figure 1).
Full ethical approval has been granted by the me-
dical ethical committee of Arnhem-Nijmegen (NL-
27905.091.09/ABR27905) and the OTiP trial is registered
at clinicaltrials.gov (NCT01336127).
Setting
For inclusion and intervention the study is embedded
within ParkinsonNet regions in the Netherlands.
ParkinsonNet comprises 65 regional networks of pro-
fessionals specialized in the treatment of patients with
Parkinson’s disease, and includes a group of specifically
trained occupational therapists [23,24]. Ten regional
hospitals and 18 occupational therapists in nine selected
ParkinsonNet regions agreed to participate. The trial
assessments and OT interventions take place at the
patient’s home.
Participants
Eligible patients have idiopathic Parkinson’s disease, live at
home, and report difficulties in valued daily activities
covering the OT domains of self-care, domestic activities,
work or leisure. Exclusion criteria are: OT intervention
in the last three months, predominating disabling comor-
bidity, and inability to complete questionnaires (that is,
due to language problems or a Mini Mental State Examin-
ation score <24). A primary informal caregiver of each pa-
tient can participate in the study when willing and
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available. Enrollment will take place over a period of 18
months (2011/2012) and procedures are given in Figure 1.
Informed consent of patient and caregiver is obtained be-
fore the first assessment.
Intervention
The OTiP intervention protocol follows the principles and
recommendations for diagnostics and interventions as
described in the Dutch guidelines for OT in Parkinson’s
disease [18,19]. The approach is client centered including
shared decision making and supporting self-management
of the patient and caregiver in dealing with problems in
daily activities. The trial therapist receives the patient’s pri-
orities in problems in daily functioning as evaluated at
baseline with the COPM [25]. The baseline COPM prior-
ities and additional information from the diagnostic phase
shape the treatment plan. The intervention is delivered at
the patient’s home for a period of ten weeks within three
months. Depending on complexity of goals, the amount of
sessions can vary with a maximum of ten sessions (only
patient goals) or 16 sessions (patient and caregiver goals)
of 45 to 60minutes. Between the three and six month
assessments, no OT will be received. An exception is
when in incidental cases of lengthy procedures to apply
for aids and adaptations, a follow-up contact after delivery
is necessary to ensure safe and proper use of the equip-
ment. Figure 2 summarizes the process and characteristics
of the OTiP intervention.
Figure 1 Flow chart of design and enrollment procedures.
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The control group does not receive any OT intervention
during the study period (six months). Thereafter, control
group patients can receive OT according to the OTiP
protocol if they wish.
In both groups, patients and caregivers are allowed to
receive other medical or allied health care interventions
except OT during the study period. We register the input
of other health and social care professionals using a care-
utilization questionnaire at each of the three assessments
focusing on the preceding three months.
Training of trial therapists
Before the start of the trial, the participating occu-
pational therapists follow a three-day training to inform
them about the study procedures and to train them to
treat the patients and caregivers according to the OTiP
intervention protocol. Special attention is given to
enhancing the therapists’ skills in coaching and motiv-
ational interviewing and in eliciting and collaboratively
defining meaningful, individualized goals with the pa-
tient and caregiver. Ways to achieve sufficient treatment
intensity in ten weeks are discussed. Halfway through
the inclusion period a booster training session (one day)
is planned. Therapists can use a secure online platform
to share issues and experiences and can consult an
expert OT (expertise in the OTiP protocol) to discuss
the intervention.
Assessment procedures
Data from patients and caregivers will be collected at
baseline (T0), three months (T1) and six months (T2) by
three research assistants (see Table 1). Another eight
Figure 2 Characteristics and process of the intervention.
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selected and trained occupational therapists will score
the Perceive Recall Plan Perform system (PRPP [26]) in
an activity that is video recorded by the assessor. All
assessors and PRPP-scorers are blinded for group alloca-
tion and each participant will be followed up by the
same assessor. Patients and caregivers also fill in self-
report questionnaires. Observational tests or measures
that follow a semi-structured interview format are
conducted in the patient’s home environment by the as-
sessor. Considering possible response fluctuations in
Parkinson’s, measures are administered within one to two
hours after medication intake (the on phase). For budget-
ary reasons, the six month assessment is conducted by
phone and therefore, does not include observational
measures.
Outcome measures
Primary outcome measure
The primary outcome for effectiveness of this interven-
tion is the patient’s self-perceived performance in daily
functioning as assessed with the Canadian Occupational
Performance Measure (COPM) (see Table 1) [25]. The
COPM is an individualized outcome measure with a
semi-structured interview format and a structured scor-
ing method. The patient identifies three to five activities
in which he encounters problems and would like to im-
prove. These activities are subsequently rated by the pa-
tient on a scale from 1 to 10 for perceived performance
capacity and level of satisfaction with this. The COPM
score for performance or satisfaction derives from
the mean score of the prioritized activities. Change is
evaluated by asking the patient to rescore performance
and satisfaction on the original priorities. Studies evaluat-
ing the psychometric properties of the COPM (in
populations of stroke and various chronic conditions)
support the validity and reliability of the COPM [41-43].
Responsiveness for change over three months was esta-
blished in a population with various conditions, and the
results support both criterion and construct responsive-
ness [44].There is a high correlation between performance
and satisfaction scores.
We selected the COPM as a primary outcome meas-
ure in our trial as it fits with the client-centered nature
and specific focus of the OTiP intervention. It addresses
the patient’s priorities and evaluation of valued activities.
In the assessment procedures, we specified the COPM
administration protocol to improve uniformity in the
semi-structured interview and in the formulation of pri-
orities while taking care to maintain the client-centered
nature of the instrument. Only the mean performance
capacity score will be used as primary outcome.
Secondary outcome measures
In Table 1 all secondary outcome measures are lis-
ted. Patients’ secondary outcomes include evaluation of
observed performance of daily activities, self-perceived
satisfaction with performance in daily activities, participa-
tion, impact of fatigue, proactive coping skills, mood,
Table 1 Outcome measures
Participant Outcome measure Instrument baseline 3 months 6 months
Patient Self-perceived performance in daily
activitiesa
Canadian Occupational Performance Measure (COPM;
performance rating) [25]
√ √ √
Self-perceived satisfaction with
performance in daily activities
Canadian Occupational Performance Measure (COPM;
satisfaction rating) [25]
√ √ √
Objective performance in daily
activities
Perceive Recall Plan Perform system (PRPP) [26] √ √ -
Participation Activity Card Sort (ACS) [27,28] √ √ -
Utrecht Scale for Evaluation of Rehabilitation Participation
(USER-P; satisfaction part) [29,30]
√ √ √
Health-related quality of life Parkinson’s Disease Questionnaire (PDQ-39) [31-33] √ √ √
Impact of fatigue Fatigue Severity Scale (FSS) [34,35] √ √ √
Mood Becks Depression Inventory (BDI) [36] √ √ √
Caregiver Perceived caregiver burden Zarit Burden Interview (ZBI) [37] √ √ √
Objective caregiver burden Objective care burden questionnaire; hours of care √ √ √
Mood Hospital Anxiety and Depression Scale (HADS) [38] √ √ √
Both Quality of life Euroqol EQ-5 D [39] √ - √
Quality of life overall Visual Analogue Scale for Quality of life; VAS QoL √ √ √
Proactive coping Utrecht Proactive Coping Competence scale (UPCC) [40] √ √ √
Resource utilization Resource utilization questionnaire: patient and caregiver
version
√ √ √
aPrimary outcome measure.
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health related quality of life, and overall quality of life. All
outcomes at the caregiver level will be secondary and in-
clude self-perceived burden of care, objective burden of
care, proactive coping skills, mood and overall quality
of life. In both patients and caregivers resource use, prod-
uctivity losses and other costs related to receiving support
or providing care are assessed with a questionnaire for the
economic evaluation
Background variables
Socio-demographic data consisting of age, gender, marital
status, education, employment status, and relationship be-
tween client and caregiver will be collected at baseline,
using a questionnaire. Patient’s disease severity will be
measured with the Unified Parkinson Disease Rating
Scale-part III [45] and with the Hoehn and Yahr (H&Y)
scale. The Mini Mental State Examination [46] is used for
cognitive screening. Comorbidity is checked with an open
question for screening purposes.
Process measures
To enable explanation of results, process data will be
collected. Therapists complete standardized OTiP patient
records and a process evaluation summary sheet to pro-
vide insight in adherence to the steps of the protocol and
actual treatment delivery (content, amount of sessions and
time spent). For each patient seen, the participating trial
therapists also record their views of effectiveness of the
intervention for the individual patient and caregiver on
the process evaluation summary sheet. We will compare
priorities identified by patients in the baseline COPM,
with goals addressed in the intervention. At the end of the
study a focus group will be conducted with all therapists
exploring their experiences and views on conducting the
OTiP intervention protocol in daily practice.
Patients and caregivers experiences with the interven-
tion will be evaluated with a custom made questionnaire
(OTiP-CQ questionnaire) based on the Consumer Qual-
ity index [47,48]. It includes mainly closed questions on
experiences with the interaction with the therapist, the
process and content of the intervention and the per-
ceived effectiveness of the intervention. Assessors register
any irregularities in adherence to assessment proce-
dures, including unblinding. Adverse events or irregular-
ities affecting protocol adherence will be registered by the
researcher.
Sample size calculation
In the main study, we intend to enroll 192 patients with
Parkinson’s and their caregivers. This is based on the
results of the OTiP pilot study with 43 participants. The
pilot resulted in a difference of 0.5 in scores on the pri-
mary outcome measure (COPM), whereas the standard
deviation was 1.35. Based on these assumptions, a t-test
would require a control group of 75 patients and an
intervention group of 150 patients for 80% power (two-
sided testing at 5%). The correlation between baseline
and outcome was approximately 0.5 and as a result, the
co-variance analysis that is planned only requires a control
group of 56 and an intervention group of 112 patients
(total of 168) [49]. In the feasibility study the dropout rate
was 7%. We expect however, that dropout rates will be
higher in this main study as the study period is doubled.
Therefore we adjust for a 10 to 15% drop- out rate and
will include approximately 192 patients.
Statistical analysis
Descriptive statistics
Means, standard deviations and frequencies will be used
to describe outcome, background and baseline variables.
Analysis effectiveness
The primary variable for effectiveness will be analyzed
in a covariance model with the COPM scores after three
months (T1) as dependent variable. The baseline COPM
scores (T0) and the minimization factors will be
covariates. Two-sided 95% confidence intervals will be
calculated. The analysis follows the principle of intention
to treat. Similarly, a secondary analysis will be done evalu-
ating the secondary outcome variables and outcomes for
six months. Regarding the caregiver outcomes, we plan a
subanalysis for caregivers with low perceived burden at
baseline (Zarit Burden Interview (ZBI) ≤20) and high
perceived burden of care (ZBI >20).
Analysis cost-effectiveness
An economic evaluation will be done from a societal per-
spective by evaluating the differences in total costs in the
control and experimental group at three and six months.
Total costs include care consumption and productivity
loss of patients and caregivers related to Parkinson’s and
caregiver’s hours of care provision to the patient. The
number of OT sessions and total time spent on OT,
will be translated as direct costs of the intervention.
Differences in costs between groups over a six-month
timeframe will be estimated using regression analysis tak-
ing into account potential co-variants. Secondly, utility
will be calculated as quality adjusted life year (QALY) over
a timeframe of six months using the trapezium rule.
QALYs for patients and caregivers are derived from
the EuroQol EQ-5D scores using the EQ-5D health tariffs
for the Dutch population [50]. Then, cost and QALY
differences are combined in an incremental cost-
effectiveness ratio (ICER), and using the bootstrap me-
thod, confidence intervals surrounding this ICER will be
estimated. We also measure cost-effectiveness by costs
per successful treatment. A successful treatment is a treat-
ment with a clinical relevant positive change in the COPM
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(+ 2 points) at six months. Reporting the ICER as cost per
successful treatment may provide decision-makers with a
relatively intuitive means of assessing cost-effectiveness,
because the denominator of the incremental ratio is
calculated using a clinically meaningful objective.
Analysis process data
A descriptive analysis will be performed for the quantitative
data on the evaluation forms of participants and assessors
and the data of therapists of the given intervention. We will
analyze the data from the focus group discussion following
the constant comparative method [51].
Discussion
Current evidence for the effectiveness of OT in
Parkinson’s disease is scarce and inconclusive. The OTiP
trial is the first large-scale randomized control trial eva-
luating the effectiveness and cost-effectiveness of client-
centered OT in Parkinson’s disease.
It is difficult to select one comprehensive outcome
measure to reflect the effectiveness of a complex interven-
tion that has a broad and individualized scope. We have
chosen an outcome measure (namely the COPM) that po-
tentially fits best with the client-centered nature of the
OTiP intervention. Additional (secondary) outcomes can
be used to capture the multimodal nature of the interven-
tion. For this purpose, we have included a range of sec-
ondary outcome measures covering the wide scope of the
OTiP intervention.
The main inclusion criteria are self-perceived problems
in valued daily activities and the extent to which patients
perceive limitations in daily activities or participation
restrictions. These inclusion criteria do not always corres-
pond with disease severity or factors like age. There-
fore, we expect great diversity in characteristics of our
participants and their contexts. This might also result in
diversity in outcomes.
To cover the large geographical spread of participants
in this multicenter trial, a relatively high number of trial
therapists will be involved to deliver the intervention. This
means that the average number of patients seen by each
therapist within the trial is low. We have taken several
measures to enhance and monitor protocol adherence, in-
cluding an online discussion platform and opportunities
for coaching during the study.
Recruitment for trials is often difficult. A strength of
this trial is the presence of the national ParkinsonNet in-
frastructure within the Netherlands [23,24]. This allows
easier access to neurologists in the participating regional
and university hospitals and their pool of patients. An-
other important and novel aspect in this study is that all
other interventions are allowed to take place during the
study. This way, the added value of guideline-based OT
in a usual multidisciplinary care setting can be evaluated.
With the comprehensive process evaluation it will also
provide information on factors that are important for fur-
ther improvement of the content or implementation of
the guidelines.
Trial status
The status of the trial is ongoing at the time of manuscript
submission. The recruitment of participants is expected to
be completed by November 2012.
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